Prajmaline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Prajmaline
Accession Number
DB13555
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • Prajmalium
Categories
UNII
75934UD4GJ
CAS number
35080-11-6
Weight
Average: 369.528
Monoisotopic: 369.253654731
Chemical Formula
C23H33N2O2
InChI Key
UAUHEPXILIZYCU-ALHOSYKFSA-N
InChI
InChI=1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19-,20-,21+,22+,23+,25-/m0/s1
IUPAC Name
(1R,9R,10S,12R,13S,14R,15R,16S,17S,18R)-13-ethyl-14,18-dihydroxy-8-methyl-15-propyl-8,15-diazahexacyclo[14.2.1.0^{1,9}.0^{2,7}.0^{10,15}.0^{12,17}]nonadeca-2(7),3,5-trien-15-ium
SMILES
CCC[N@@+]12[C@H]3C[C@]45[C@H](O)[C@H]3[C@@H](C[C@H]1[C@@H]4N(C)C1=C5C=CC=C1)[C@H](CC)[C@H]2O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbexinostatThe risk or severity of QTc prolongation can be increased when Prajmaline is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when Prajmaline is combined with Acebutolol.
AceprometazineThe risk or severity of QTc prolongation can be increased when Prajmaline is combined with Aceprometazine.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Prajmaline.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Prajmaline is combined with Acetyldigoxin.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Prajmaline.
AdenosineThe risk or severity of QTc prolongation can be increased when Prajmaline is combined with Adenosine.
AgmatineAgmatine may increase the arrhythmogenic activities of Prajmaline.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Prajmaline.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Prajmaline.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
34986954
ChEBI
135560
Wikipedia
Prajmaline
ATC Codes
C01BA08 — Prajmaline

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0299 mg/mLALOGPS
logP2.24ALOGPS
logP-1.4ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)12.01ChemAxon
pKa (Strongest Basic)-0.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity117.75 m3·mol-1ChemAxon
Polarizability42.74 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as ajmaline-sarpagine alkaloids. These are organic compounds containing either of the ajmalan, sarpagan skeleton, or derivative thereof. The Sarpagine (Akuammidine) group, based on the sarpagan nucleus, arises from bond formation between C-16 and C-5 of the corynantheine precursor. Ajmaline alkaloids are based on a 17,19-secoyohimban skeleton (oxayohimban) which is invariably present as an ether.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ajmaline-sarpagine alkaloids
Sub Class
Not Available
Direct Parent
Ajmaline-sarpagine alkaloids
Alternative Parents
Beta carbolines / Quinolizidines / Quinuclidines / Dialkylarylamines / Aralkylamines / Azepanes / Benzenoids / Piperidines / Tetraalkylammonium salts / Hemiaminals
show 7 more
Substituents
Sarpagine-skeleton / Beta-carboline / Pyridoindole / Quinolizidine / Indole or derivatives / Dialkylarylamine / Quinuclidine / Tertiary aliphatic/aromatic amine / Azepane / Aralkylamine
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:44 / Updated on June 04, 2019 07:55